Scarica l'app Stockscreener
14.30
1.27%
0.18
Precedente Chiudi:
$14.12
Aprire:
$14.07
Volume 24 ore:
879.17K
Relative Volume:
0.67
Capitalizzazione di mercato:
$784.60M
Reddito:
$15.84M
Utile/perdita netta:
$-308.48M
Rapporto P/E:
-2.2068
EPS:
-6.48
Flusso di cassa netto:
$-153.08M
1 W Prestazione:
+2.14%
1M Prestazione:
-0.69%
6M Prestazione:
+7.52%
1 anno Prestazione:
+98.06%
Intervallo 1D:
$13.86
$14.71
Intervallo di 1 settimana:
$12.89
$14.71
Portata 52W:
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
14.30 | 774.72M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
Institutional Ownership Dominates uniQure N.V., Hedge Funds Hold 19% - AInvest
uniQure N.V. (NASDAQ:QURE) is favoured by institutional owners who hold 55% of the company - uk.finance.yahoo.com
Uniqure N.V. shares rise 1.04% after-hours following PTC Therapeutics' positive Q2 earnings report. - AInvest
Aberdeen Group Expands Stake in uniQure with Strategic Acquisition - AInvest
Aberdeen Group plc Expands Stake in uniQure NV with Strategic Ac - GuruFocus
Is uniQure N.V. a good long term investmentGet exclusive access to premium stock research - Jammu Links News
What is uniQure N.V. company’s growth strategyStrongest growth potential - Jammu Links News
Should I hold or sell uniQure N.V. stock in 2025Unlock daily market insights for better trades - Jammu Links News
What makes uniQure N.V. stock price move sharplyBuild a strong portfolio for long-term success - Jammu Links News
What drives uniQure N.V. stock priceUnprecedented market success - Jammu Links News
Is uniQure N.V. a growth stock or a value stockMaximize returns with disciplined investment techniques - Jammu Links News
What is the risk reward ratio of investing in uniQure N.V. stockOutstanding growth strategies - Jammu Links News
What are the latest earnings results for uniQure N.V.Discover undervalued stocks before they soar - Jammu Links News
How does uniQure N.V. compare to its industry peersMaximize your gains with expert trading tips - Jammu Links News
Is uniQure N.V. stock overvalued or undervaluedDiscover high-impact stocks for your portfolio - Jammu Links News
What analysts say about uniQure N.V. stockDiscover breakthrough stocks before the crowd - Jammu Links News
How strong is uniQure N.V. company’s balance sheetBuild wealth faster with professional insights - Jammu Links News
What are the technical indicators suggesting about uniQure N.V.High-octane gains - Jammu Links News
Why is uniQure N.V. stock attracting strong analyst attentionEntry Signal Signals To Watch Now - Jammu Links News
UniQure N.V. (NASDAQ:QURE) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $35 to $35 - 富途牛牛
uniQure Reports Q2 2025 Progress and Financials - TipRanks
uniQure’s AMT-130 Gene Therapy for Huntington’s Disease on Track for Q1 2026 BLA Submission After FDA Alignment - Insider Monkey
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Zacks Investment Research
uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call Transcript - Insider Monkey
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
uniQure N.V. Earnings Call: Progress Amid Challenges - TipRanks
Chardan Capital Analyst Downgrades uniQure Price Target to $35.00, Maintains Buy Rating - AInvest
What Caused uniQure’s (QURE.O) Sudden Intraday Surge? - AInvest
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
UniQure outlines planned BLA submission for AMT-130 in Q1 2026 amid regulatory alignment and pipeline momentum - MSN
UniQure shares rise 9.65% premarket after FDA alignment on AMT-130 statistical analysis plan and CMC requirements. - AInvest
UniQure: Q2 Earnings Snapshot - Huron Daily Tribune
UniQure shares rise 12.35% premarket after FDA alignment on AMT-130 and positive clinical data. - AInvest
uniQure NV (QURE) Q2 2025 Earnings Call Highlights: Navigating R - GuruFocus
Chardan Capital maintains Buy rating for uniQure with $35 PT. - AInvest
Mizuho Securities Maintains UniQure NV(QURE.US) With Hold Rating - 富途牛牛
uniQure shares tumble as Q2 revenue misses expectations By Investing.com - Investing.com Canada
uniQure shares tumble as Q2 revenue misses expectations - Investing.com
uniQure Announces $200 Million Sales Agreement - TipRanks
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):